BMS to beef up portfolio of diabetes medicines

Published: 2012-09-11 06:57:00

Updated: 2012-09-11 06:57:00

U.S. based Bristol-Myers Squibb (BMS) is set to increase and promote its innovative portfolio of diabetes medicines, extending its reach across the spectrum of treatment options.

Both BMS and AstraZeneca successfully completed the acquisition of Amylin Pharmaceuticals last month. AstraZeneca made an initial payment of approximately $3.2 billion to Amylin Pharmaceuticals, now a wholly-owned s...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.